The study describes the synthesis of novel indole-based PAR4 antagonists and a high-throughput screening assay, identifying new scaffolds for potential antithrombotic drug development.
Answers are grounded in this paper and cite their sources.
Identifies candidate PAR4 antagonists for testing; leaves open translation to clinical antithrombotic efficacy.
Protease activated receptor-4 (PAR4) is one of the thrombin receptors on human platelets and is a potential target for the management of thrombotic disorders. We sought to develop potent, selective, and novel PAR4 antagonists to test the role of PAR4 in thrombosis and hemostasis. Development of an expedient three-step synthetic route to access a novel series of indole-based PAR4 antagonists also necessitated the development of a platelet based high-throughput screening assay. Screening and subsequent structure activity relationship analysis yielded several selective PAR4 antagonists as well as possible new scaffolds for future antagonist development.
No takes yet. Share an insight, caveat, or question.
Young et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: